Your Health, We Care
Release date: 2024-07-09 14:59:23 Article From: Lucius Laos Recommended: 292
Lysodren is a drug used to treat adrenal cortical CA disease, with its target being the steroid hormone receptor. Adrenal cortical CA is a rare but invasive CA disease that originates from the tuber of the adrenal cortex.
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational s···【more】
Recommended：45Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug CompanyRelocation Background and Strategic ShiftLucius Pharmaceuticals was fo···【more】
Recommended：99Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for generic drugs, leveraging the WTO-granted patent exemption for least-developed countries. Among them, Lu···【more】
Recommended：104Release date: 2026-07-22
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended：109Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended：128Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended：154Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended：126Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended：130Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended：127Release date: 2026-07-09
Laos's pharmaceutical industry started late and remains relatively small in scale; for a long time, domestic drug supply has relied on imports from China, India, and other coun···【more】
Recommended：148Release date: 2026-07-08
Before 2020, there were only a handful of legally approved local pharmaceutical manufacturers in Laos, mostly small state-owned factories with outdated equipment. Within just a few···【more】
Recommended：165Release date: 2026-07-07
With generic drugs as its core, Laos' pharmaceutical industry has formed an industrial pattern featuring coordination between state-owned and private enterprises as well as loc···【more】
Recommended：192Release date: 2026-07-02
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended：825Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended：785Release date: 2024-07-09
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the class of ALK inhibitors. Unlike traditional chemotherapy, it does not act by kill···【more】
Recommended：16Release date: 2026-07-30
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet. The recommended dose is once daily, one tablet per day (the specific dose is de···【more】
Recommended：35Release date: 2026-07-29
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies for DacomitinibRash and exfoliative skin reactions are highly characteristic adv···【more】
Recommended：91Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended：98Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended：129Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended：134Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended：139Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended：161Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended：273Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended：595Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination with abiraterone acetate (brand name: Akeega, Janssen Biotech, Inc.) plus predni···【more】
Recommended：549Release date: 2025-12-15
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplantation (HSCT) therapy for th···【more】
Recommended：576Release date: 2025-12-10
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet.···【more】
Recommended：[list:visits]2026-29-07
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital ···【more】
Recommended：[list:visits]2026-28-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended：[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
